Table 1. Characteristics of Included Studies.
| Study | Design | Follow-Up (Months) | Country | Participants (n) | MS Criteria | HD (Months) | Factors Adjustment | |
|---|---|---|---|---|---|---|---|---|
| MS | Non-MS | |||||||
| Yang 2007 | Prospective cohort | 36 | Taiwan | 108 | 127 | Modified Asian criteria of NCEP ATP III | 50.8 | |
| Xie 2012 | Prospective cohort | 36-42 | China | 46 | 111 | IDF | 44 | |
| Wu 2011 | Prospective cohort | 36 | Taiwan | 46 | 45 | NCEP, IDF | 25 | Age, hemoglobin, albumin, hs-CRP |
| Vogt 2014 | Prospective cohort | 64 | Brazil | 50 | 49 | NCEP ATP III, IDF | 42 | Age, sex, serum creatinine |
| Prasad 2013 | Prospective cohort | 24 | India | 84 | 79 | Modified Asian criteria of NCEP ATP III | PD at least 3 months | Age, gender, comorbidities, serum albumin, peritonitis |
| Park 2010 | Prospective cohort | 60 | Korea | 50 | 56 | NCEP ATP III | CAPD 83.4 | Age, sex, albumin, hematocrit and dialysis duration |
| Liao 2011 | Prospective cohort | 49.2 | Taiwan | 90 | 132 | NCEP ATP III | PD at least 3 months | History of smoking, pre-existing CVD, residual GFR, LDL-C, serum albumin, CRP |
| Johnson 2007 | prospective, open-label randomized controlled trial | 24 | Australia | 61 | 139 | WHO | HD 1.5 years PD 0.9 year | Residual renal function, adiponectin, albumin, calcium, phosphate, free fatty acid, homocysteine, CRP |
Abbreviation: CVD, cardiovascular disease; CRP: C-reactive protein; Non-MS, non-metabolic syndrome; HD, hemodialysis; hs-CRP, high-sensitivity C-reactive protein; GFR, glomerular filtration rate; LDL-C, LDL cholesterol; MS, metabolic syndrome; PD, peritoneal dialysis.